BOSTON ( TheStreet) -- Keryx Pharmaceuticals ( KERX) will be put up for sale if the company's experimental colon cancer drug succeeds in a late-stage study early next year, the company's CEO said Wednesday.

"Given the market opportunity in colon cancer, it would be very nice to sell the company," Keryx CEO Ron Bentsur told investors at the Stifel Nicolaus Healthcare Conference.

Bentsur added that Keryx would consider licensing its colon cancer drug, known as perifosine, or perhaps even sell the drug on its own. Still, his "top priority" would be to find a large pharmaceutical company to acquire the company outright.

A phase III study of perifosine in colon cancer is nearing completion, with a survival analysis expected early in the first quarter of 2012. Keryx had initially anticipated having top-line results from the perifosine colon cancer study ready in the fourth quarter of this year, but the study's "event rate" -- i.e. the rate at which patients are dying -- is a bit slower than Keryx has initially forecast, Bentsur said.

Does this mean that perifosine is working and that the study will be a success?

"It's hard to draw conclusions" from extending the perifosine data timelines out a bit," he warned. Bentsur obviously doesn't want to fall into the nasty circle of hell that has enveloped fellow biotech chief executives who dared to predict victory in drug trials that took longer to report results than initially expected.

Perifosine is an old drug that's been around the block more than once, which should give investors some pause. But Keryx also has solid perifosine data from a phase II study demonstrating that the drug can prolong survival in advanced colon cancer patients.

This phase II study was small, enrolling only 38 patients, which is why a phase III study will tell the tale of perifosine (and also why the study's outcome still carries significant risk.)

The patients enrolling in the phase III study all have advanced colon cancer that is no longer responding to currently approved drugs. Even as a "salvage" or last-line therapy, perifosine's commercial opportunity is significant because the drug, if approved, will have data demonstrating a survival benefit.

About 25,000 colon cancer patients in the U.S. reach the stage at which they'd be eligible for treatment with perifosine. While Keryx hasn't discussed pricing, it's not hard to put together a revenue model in which perifosine achieves peak sales of $500 million to $750 million.

Keryx is also conducting a perifosine a phase III study in multiple myeloma, which could be upside if that study also works. And the company has another drug, Zerenex, in a late-stage study of kidney disease (dialysis) patients.

For now, investors are focused on the perifosine colon cancer study, and rightly so with results right around the corner.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.